|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.32 SEK | +0.44% |
|
-6.76% | +4.27% |
| Apr. 18 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 | |
| Apr. 18 | Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Hansa Biopharma AB (publ) reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was SEK 50.41 million compared to SEK 30.77 million a year ago. Net loss was SEK 124.46 million compared to SEK 148.68 million a year ago.
Basic loss per share from continuing operations was SEK 2.36 compared to SEK 3.22 a year ago. Diluted loss per share from continuing operations was SEK 2.36 compared to SEK 3.22 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +4.27% | 137M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
HANSA BIOPHARMA AB 
